Yu-Ling Lin Selected Research

butylidenephthalide

1/2021	Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation of n-butylidenephthalide in breast cancer cells.
1/2021	Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma.
5/2020	Antitumor Effects of N-Butylidenephthalide Encapsulated in Lipopolyplexs in Colorectal Cancer Cells.
1/2020	Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood-Brain Barrier and Suppresses Growth of Glioblastoma.
12/2018	Antitumor Effect of n-Butylidenephthalide Encapsulated on B16/F10 Melanoma Cells In Vitro with a Polycationic Liposome Containing PEI and Polyethylene Glycol Complex.
1/2015	Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu-Ling Lin Research Topics

Disease

30	Neoplasms (Cancer) 05/2022 - 10/2010
3	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2017
3	Breast Neoplasms (Breast Cancer) 01/2021 - 02/2016
2	Inflammation (Inflammations) 01/2022 - 01/2022
2	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 05/2020
2	Brain Neoplasms (Brain Tumor) 05/2020 - 01/2013
2	Colonic Neoplasms (Colon Cancer) 05/2020 - 04/2012
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2015
2	Lung Neoplasms (Lung Cancer) 10/2019 - 02/2015
2	Melanoma (Melanoma, Malignant) 12/2018 - 09/2017
2	Hypoxia (Hypoxemia) 01/2018 - 04/2010
1	Insulin Resistance 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Obesity 01/2022
1	Fatty Liver 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Sepsis (Septicemia) 11/2021
1	Multiple Organ Failure (MODS) 11/2021
1	Bacteremia 10/2021
1	Carcinoma (Carcinomatosis) 10/2021
1	Fever (Fevers) 10/2021
1	Wounds and Injuries (Trauma) 10/2021
1	Demyelinating Diseases (Demyelinating Disease) 03/2021
1	Colorectal Neoplasms (Colorectal Cancer) 05/2020
1	Body Weight (Weight, Body) 01/2020
1	Anemia 12/2018
1	Chest Pain (Chest Pains) 10/2018
1	Ascites 10/2018
1	Mouth Neoplasms (Oral Cancer) 10/2018
1	Pericarditis 10/2018
1	Persistent Infection 06/2018
1	Carcinogenesis 06/2018
1	Stomach Neoplasms (Stomach Cancer) 01/2018
1	Chronic Disease (Chronic Diseases) 05/2016

Drug/Important Bio-Agent (IBA)

10	Pharmaceutical PreparationsIBA 01/2021 - 10/2010
6	butylidenephthalideIBA 01/2021 - 01/2015
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2010
3	Antineoplastic Agents (Antineoplastics)IBA 11/2021 - 04/2012
3	Liposomes (Liposome)IBA 01/2021 - 12/2018
2	CytokinesIBA 05/2022 - 11/2021
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2016
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2022
2	NF-kappa B (NF-kB)IBA 01/2022 - 04/2010
2	poly(ethylene glycol)-co-poly(ethyleneimine)IBA 01/2021 - 02/2019
2	PolyethyleneimineIBA 05/2020 - 12/2018
2	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 05/2020 - 12/2018
2	Therapeutic UsesIBA 01/2020 - 05/2011
2	Actins (F Actin)IBA 10/2019 - 09/2017
2	AntibodiesIBA 01/2018 - 11/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2011 - 11/2010
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 05/2011 - 11/2010
1	CholesterolIBA 01/2022
1	Insulin (Novolin)FDA Link 01/2022
1	Complementary DNA (cDNA)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	BiflavonoidsIBA 11/2021
1	Serum AlbuminIBA 10/2021
1	Biological ProductsIBA 10/2021
1	CollagenIBA 03/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Drug CarriersIBA 05/2020
1	Cytotoxins (Cytolysins)IBA 05/2020
1	2',3-dimethyl-4-aminobiphenylIBA 01/2020
1	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 10/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2019
1	Tyrosine (L-Tyrosine)FDA Link 10/2019
1	Protein Tyrosine PhosphatasesIBA 10/2019
1	Neoplasm AntibodiesIBA 02/2019
1	Epidermal Growth Factor (EGF)IBA 02/2019
1	Trastuzumab (Herceptin)FDA Link 02/2019
1	Saline SolutionIBA 10/2018
1	Chaperonin 60IBA 06/2018
1	Virulence Factors (Pathogenicity Factors)IBA 06/2018
1	IntegrinsIBA 01/2018
1	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 01/2018
1	Endoplasmic Reticulum Chaperone BiPIBA 11/2016
1	AutoantibodiesIBA 11/2016
1	Masoprocol (Actinex)FDA Link 11/2016
1	LignansIBA 11/2016
1	Surface Antigens (Surface Antigen)IBA 11/2016
1	Adenosine Triphosphate (ATP)IBA 11/2016
1	Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)IBA 05/2016
1	Lipid NanoparticlesIBA 05/2016
1	ChitosanIBA 05/2016
1	Estrogen ReceptorsIBA 02/2016
1	Fluorescent Dyes (Fluorescent Probes)IBA 02/2016
1	Tamoxifen FDA LinkGeneric 02/2016
1	Fluorouracil (Carac)FDA LinkGeneric 01/2016

Therapy/Procedure

10	Therapeutics 01/2021 - 09/2006
2	Radiofrequency Ablation 10/2021 - 10/2018
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 12/2018 - 01/2013
1	Complementary Therapies (Alternative Medicine) 01/2022
1	General Anesthesia 10/2021
1	Length of Stay 10/2021
1	Intraperitoneal Injections 01/2020
1	Aftercare (After-Treatment) 12/2018
1	Catheter Ablation 10/2018
1	Chemoprevention 09/2017
1	Oral Administration 05/2016